2032 related articles for article (PubMed ID: 31068700)
1. Next-generation characterization of the Cancer Cell Line Encyclopedia.
Ghandi M; Huang FW; Jané-Valbuena J; Kryukov GV; Lo CC; McDonald ER; Barretina J; Gelfand ET; Bielski CM; Li H; Hu K; Andreev-Drakhlin AY; Kim J; Hess JM; Haas BJ; Aguet F; Weir BA; Rothberg MV; Paolella BR; Lawrence MS; Akbani R; Lu Y; Tiv HL; Gokhale PC; de Weck A; Mansour AA; Oh C; Shih J; Hadi K; Rosen Y; Bistline J; Venkatesan K; Reddy A; Sonkin D; Liu M; Lehar J; Korn JM; Porter DA; Jones MD; Golji J; Caponigro G; Taylor JE; Dunning CM; Creech AL; Warren AC; McFarland JM; Zamanighomi M; Kauffmann A; Stransky N; Imielinski M; Maruvka YE; Cherniack AD; Tsherniak A; Vazquez F; Jaffe JD; Lane AA; Weinstock DM; Johannessen CM; Morrissey MP; Stegmeier F; Schlegel R; Hahn WC; Getz G; Mills GB; Boehm JS; Golub TR; Garraway LA; Sellers WR
Nature; 2019 May; 569(7757):503-508. PubMed ID: 31068700
[TBL] [Abstract][Full Text] [Related]
2. Predicting Cancer Cell Line Dependencies From the Protein Expression Data of Reverse-Phase Protein Arrays.
Chen MM; Li J; Mills GB; Liang H
JCO Clin Cancer Inform; 2020 Apr; 4():357-366. PubMed ID: 32330068
[TBL] [Abstract][Full Text] [Related]
3. New tools for old drugs: Functional genetic screens to optimize current chemotherapy.
Gerhards NM; Rottenberg S
Drug Resist Updat; 2018 Jan; 36():30-46. PubMed ID: 29499836
[TBL] [Abstract][Full Text] [Related]
4. Data Mining Approaches for Genomic Biomarker Development: Applications Using Drug Screening Data from the Cancer Genome Project and the Cancer Cell Line Encyclopedia.
Covell DG
PLoS One; 2015; 10(7):e0127433. PubMed ID: 26132924
[TBL] [Abstract][Full Text] [Related]
5. Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Behan FM; Iorio F; Picco G; Gonçalves E; Beaver CM; Migliardi G; Santos R; Rao Y; Sassi F; Pinnelli M; Ansari R; Harper S; Jackson DA; McRae R; Pooley R; Wilkinson P; van der Meer D; Dow D; Buser-Doepner C; Bertotti A; Trusolino L; Stronach EA; Saez-Rodriguez J; Yusa K; Garnett MJ
Nature; 2019 Apr; 568(7753):511-516. PubMed ID: 30971826
[TBL] [Abstract][Full Text] [Related]
6. A Road Map to Personalizing Targeted Cancer Therapies Using Synthetic Lethality.
Parameswaran S; Kundapur D; Vizeacoumar FS; Freywald A; Uppalapati M; Vizeacoumar FJ
Trends Cancer; 2019 Jan; 5(1):11-29. PubMed ID: 30616753
[TBL] [Abstract][Full Text] [Related]
7. Project Score database: a resource for investigating cancer cell dependencies and prioritizing therapeutic targets.
Dwane L; Behan FM; Gonçalves E; Lightfoot H; Yang W; van der Meer D; Shepherd R; Pignatelli M; Iorio F; Garnett MJ
Nucleic Acids Res; 2021 Jan; 49(D1):D1365-D1372. PubMed ID: 33068406
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic Alterations of Heat Shock Proteins (HSPs) in Cancer.
Ban HS; Han TS; Hur K; Cho HS
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31557887
[TBL] [Abstract][Full Text] [Related]
9. Using drug response data to identify molecular effectors, and molecular "omic" data to identify candidate drugs in cancer.
Reinhold WC; Varma S; Rajapakse VN; Luna A; Sousa FG; Kohn KW; Pommier YG
Hum Genet; 2015 Jan; 134(1):3-11. PubMed ID: 25213708
[TBL] [Abstract][Full Text] [Related]
10. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
[TBL] [Abstract][Full Text] [Related]
11. A pan-cancer analysis of progression mechanisms and drug sensitivity in cancer cell lines.
Fleck JL; Pavel AB; Cassandras CG
Mol Omics; 2019 Dec; 15(6):399-405. PubMed ID: 31570905
[TBL] [Abstract][Full Text] [Related]
12. Establishment and characterization of multi-drug resistant, prostate carcinoma-initiating stem-like cells from human prostate cancer cell lines 22RV1.
Liu T; Xu F; Du X; Lai D; Liu T; Zhao Y; Huang Q; Jiang L; Huang W; Cheng W; Liu Z
Mol Cell Biochem; 2010 Jul; 340(1-2):265-73. PubMed ID: 20224986
[TBL] [Abstract][Full Text] [Related]
13. Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines.
Zhao W; Li J; Chen MM; Luo Y; Ju Z; Nesser NK; Johnson-Camacho K; Boniface CT; Lawrence Y; Pande NT; Davies MA; Herlyn M; Muranen T; Zervantonakis IK; von Euw E; Schultz A; Kumar SV; Korkut A; Spellman PT; Akbani R; Slamon DJ; Gray JW; Brugge JS; Lu Y; Mills GB; Liang H
Cancer Cell; 2020 Dec; 38(6):829-843.e4. PubMed ID: 33157050
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets.
Chekhun VF; Lukyanova NY; Kovalchuk O; Tryndyak VP; Pogribny IP
Mol Cancer Ther; 2007 Mar; 6(3):1089-98. PubMed ID: 17363502
[TBL] [Abstract][Full Text] [Related]
15. Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells.
Wang H; Fu C; Du J; Wang H; He R; Yin X; Li H; Li X; Wang H; Li K; Zheng L; Liu Z; Qiu Y
J Exp Clin Cancer Res; 2020 Feb; 39(1):29. PubMed ID: 32024543
[TBL] [Abstract][Full Text] [Related]
16. Improved anticancer drug response prediction in cell lines using matrix factorization with similarity regularization.
Wang L; Li X; Zhang L; Gao Q
BMC Cancer; 2017 Aug; 17(1):513. PubMed ID: 28768489
[TBL] [Abstract][Full Text] [Related]
17. Differentially expressed genes are marked by histone 3 lysine 9 trimethylation in human cancer cells.
Wiencke JK; Zheng S; Morrison Z; Yeh RF
Oncogene; 2008 Apr; 27(17):2412-21. PubMed ID: 17968314
[TBL] [Abstract][Full Text] [Related]
18. Crude phenolic extracts from extra virgin olive oil circumvent de novo breast cancer resistance to HER1/HER2-targeting drugs by inducing GADD45-sensed cellular stress, G2/M arrest and hyperacetylation of Histone H3.
Oliveras-Ferraros C; Fernández-Arroyo S; Vazquez-Martin A; Lozano-Sánchez J; Cufí S; Joven J; Micol V; Fernández-Gutiérrez A; Segura-Carretero A; Menendez JA
Int J Oncol; 2011 Jun; 38(6):1533-47. PubMed ID: 21455577
[TBL] [Abstract][Full Text] [Related]
19. Hacking the Cancer Genome: Profiling Therapeutically Actionable Long Non-coding RNAs Using CRISPR-Cas9 Screening.
Esposito R; Bosch N; Lanzós A; Polidori T; Pulido-Quetglas C; Johnson R
Cancer Cell; 2019 Apr; 35(4):545-557. PubMed ID: 30827888
[TBL] [Abstract][Full Text] [Related]
20. CRISPR/Cas9-mediated knockout of NSD1 suppresses the hepatocellular carcinoma development via the NSD1/H3/Wnt10b signaling pathway.
Zhang S; Zhang F; Chen Q; Wan C; Xiong J; Xu J
J Exp Clin Cancer Res; 2019 Nov; 38(1):467. PubMed ID: 31727171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
